HUTCHMED (China) Limited (HK:0013) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
HUTCHMED (China) Limited is set to showcase new clinical data at the 2024 ASH Annual Meeting and ESMO Asia Congress, highlighting the efficacy of its drug sovleplenib in treating chronic primary immune thrombocytopenia in China. The data reveals promising long-term results, with a significant percentage of patients showing sustained improvement in platelet counts. This development underscores HUTCHMED’s commitment to advancing cancer and immunological therapies.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
